AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|
20.6 C
New York
Sunday, July 26, 2026

Tag: blood glucose

newssourceFORcompanyinformationcontent1releasesmarket

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

High-tech Health for Students: Health-E Commerce® Highlights 10 Ways to Use Flexible Spending Accounts (FSA) and Health Savings Accounts (HSAs) for Digital Healthcare Products...

Tax-free FSA and HSA funds can be used to purchase health devices at FSA Store and HSA Store that treat conditions like acne, diabetes,...

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBlood glucose

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers